In this issue of Circulation: Heart Failure, Turgeon et al 7 conducted a qualitative needs ... Could engaging patients in their treatment decisions also, in turn, improve GDMT? The current study and ...

In a trial-level meta-analysis published in the journal Circulation, researchers assessed the effects of sodium-glucose co-transporter 2 (SGLT2 ... cardiovascular disease (ASCVD), heart failure ...

alert system did not significantly increase the prescription of guideline-directed medical therapies (GDMT) at hospital discharge for patients with acute heart failure (AHF). Investigators wanted ...

These labels apply only to patients who have not previously had an LVEF ≤40% (these are referred to as heart failure with improved ejection fraction). SGLT2 inhibitors are recommended as the first ...

Sodium-glucose transporter 2 (SGLT2) inhibitors are safe and well-tolerated in people with heart failure (HF) related to adult congenital heart disease (ACHD) and associated with reduced ...

SGLT2 inhibitors not only were safe in adult patients with congenital heart disease who develop heart failure but also were associated with reduced hospitalizations. Sodium-glucose transporter 2 ...

Advance in the Treatment of Acute Heart Failure Identified Apr. 25, 2024 — A multicenter study has identified a potential new treatment for acute heart failure, a leading cause of ...

A progressive heart disease that affects pumping action of the heart muscles. This causes fatigue, shortness of breath. This reduces the blood supplied throughout the body, leading to tiredness ...

Weight-Loss Drug Wegovy Slashes Risk of Death in Some People with Heart Disease The active ingredient in Wegovy and Ozempic reduced the risk of heart attacks and strokes in a large trial of people ...